← All candidates
65 insider filings on record.
Gilbert Ray Cisneros, Jr.Small Business · Armed Servicestraded 30 Jul · filed 4 Sep · selfBuy$1K–$15Kself30 Jul48d ago4 Sep12d ago65 filings on record.
PRAXPraxis Precision Medicines, Inc.
NasdaqGS · Healthcare · $10.06B
$334.58
-1.18% · Sep 11
65 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 16 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what PRAX ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$10.06B
Float
25.1M
90% public
Short % float
Pro
Congress
▸ Disclosures lag trades by 30–45 days.
1 disclosure12 mo
MemberTypeAmountOwnerTradedFiled
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
60 more transactions on Pro →Context
Wall St
$619.11 avg target
+85.0% vs today · 18 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$3.20 act+$0.48
Q4 '25−$3.50 act−$0.37
Q3 '25−$3.36 act+$0.13
Q2 '25−$3.31 act+$0.05
Coverage
Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy DesignationInvestorsHub · 06-22Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack UpSimply Wall St. · 06-15BTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX)Insider Monkey · 06-11Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study FindingsInsider Monkey · 06-05
The file stays open
65 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice